Acceleron Pharma Inc (XLRN) CFO Kevin F. Mclaughlin Sells 4,000 Shares
Acceleron Pharma Inc (NASDAQ:XLRN) CFO Kevin F. Mclaughlin sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $42.42, for a total transaction of $169,680.00. Following the completion of the transaction, the chief financial officer now owns 45,300 shares of the company’s stock, valued at $1,921,626. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Acceleron Pharma Inc (NASDAQ XLRN) opened at $44.20 on Tuesday. The company has a market cap of $1,988.98, a PE ratio of -17.07 and a beta of 1.59. Acceleron Pharma Inc has a fifty-two week low of $23.07 and a fifty-two week high of $46.93.
Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.02. The company had revenue of $3.00 million for the quarter, compared to the consensus estimate of $3.52 million. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. The firm’s revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.55) EPS. equities analysts expect that Acceleron Pharma Inc will post -2.65 EPS for the current year.
XLRN has been the subject of a number of recent research reports. HC Wainwright boosted their price objective on shares of Acceleron Pharma from $57.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, November 7th. Oppenheimer reissued a “hold” rating on shares of Acceleron Pharma in a research report on Monday, December 11th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $55.00 target price on shares of Acceleron Pharma in a report on Thursday, January 18th. ValuEngine downgraded shares of Acceleron Pharma from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Finally, Cann reaffirmed a “hold” rating on shares of Acceleron Pharma in a report on Monday, January 8th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the company’s stock. Acceleron Pharma presently has a consensus rating of “Buy” and an average target price of $44.81.
COPYRIGHT VIOLATION WARNING: “Acceleron Pharma Inc (XLRN) CFO Kevin F. Mclaughlin Sells 4,000 Shares” was originally reported by Marea Informative and is the property of of Marea Informative. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.mareainformativa.com/2018/01/30/insider-selling-acceleron-pharma-inc-xlrn-cfo-sells-169680-00-in-stock-updated-updated-updated.html.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.